SIETES :: 92636 citas

Resultados de la búsqueda por SAVOR TIMI-53

1.

Abrahami D, Douros A, Yin H, Hu OHY, Faillie J-L, Montastruc F, Platt RW, Bouganim N, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:5 de diciembre. [Ref.ID 102894]

2.

Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017;357:j2499. [Ref.ID 101630]

3.

Anónimo. An update on the "gliptins". Drug Ther Bull 2016;54:138-41. [Ref.ID 101014]

4.

Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P, for the CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 2016;374:1145-54. [Ref.ID 100077]

5.

Bolen SD, Maruthur NM. The safety of incretin based drug treatments for type 2 diabetes. BMJ 2016;352:i801. [Ref.ID 100062]

6.

Holman RR, Peterson ED. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2479. [Ref.ID 99762]

7.

Rutter MK, Wright AK, Ashcroft DM. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2478. [Ref.ID 99761]

8.

Anónimo. Saxagliptin and heart failure: what’s the risk?. NPS MedicineWise 2014:24 de abril. [Ref.ID 97513]

9.

Anónimo. FDA Drug Safety Communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). FDA U.S. Food and Drug Administration 2014:11 de febrero. [Ref.ID 97106]

10.

White WB, Zannad F. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med 2014;370:484. [Ref.ID 97069]

11.

Scirica BM, Braunwald E, Bhatt DL. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med 2014;370:483-4. [Ref.ID 97068]

12.

Standl E. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med 2014;370:483. [Ref.ID 97067]

13.

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. [Ref.ID 96331]

14.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. [Ref.ID 96330]

15.

Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs - Insights from the rosiglitazone experience. N Engl J Med 2013;369:1285-7. [Ref.ID 96329]